Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stanford V Chemotherapy and Radiotherapy in Early Hodgkin's Disease
NCT00002714Phase 2Completed
- Sponsor
- Stanford University
- Start
- Apr 1995
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mechlorethamine, doxorubicin, vinblastine, prednisone, vincristine and 2 more in Hodgkin lymphoma (HL), sponsored by Stanford University. Primary endpoints: Progression-Free Survival at 10 years and Overall Survival at 10 years. Started Apr 1995; status: completed.
02
Drugs
mechlorethaminedoxorubicinvinblastineprednisonevincristine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00002714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002714.